Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 27, 2007

BioLineRx In-Licenses Treatment for Acute Kidney Injury

  • BioLineRx signed a worldwide, exclusive license agreement with Gene Vector Technologies for the development and commercialization of BL-4040, a drug for the treatment of acute kidney injury (AKI).

    BL-4040 is a genetically engineered version of the major capsid protein VP1, derived from the outer protein shell of the virus SV40. By boosting the natural stress response and survival pathways of kidney cells, BL-4040 may prevent apoptosis of kidney cells following AKI, the companies explain.

    “BL-4040 is extremely effective in mice, relatively simple to produce, and nontoxic even at very high doses,” says Morris C. Laster, M.D., CEO of BioLineRx. “We believe that BL-4040 offers the potential for a highly effective and safe therapy that taps into the natural defense systems of the body.”

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »